作者:John P. Duffy、Edmund M. Harrington、Francesco G. Salituro、John E. Cochran、Jeremy Green、Huai Gao、Guy W. Bemis、Ghotas Evindar、Vincent P. Galullo、Pamella J. Ford、Ursula A. Germann、Keith P. Wilson、Steven F. Bellon、Guanging Chen、Paul Taslimi、Peter Jones、Cassey Huang、S. Pazhanisamy、Yow-Ming Wang、Mark A. Murcko、Michael S.S. Su
DOI:10.1021/ml2001455
日期:2011.10.13
The synthesis of novel, selective, orally active 2,5-disubstituted 6H-pyrimido[1,6-b]pyridazin-6-one p38alpha inhibitors is described. Application of structural information from enzyme-ligand complexes guided the selection of screening compounds, leading to the identification of a novel class of p38alpha inhibitors containing a previously unreported bicyclic heterocycle core. Advancing the SAR of this
描述了新型的,选择性的,口服活性的2,5-二取代的6H-嘧啶并[1,6-b]哒嗪-6-一个p38alpha抑制剂的合成。来自酶-配体复合物的结构信息的应用指导了筛选化合物的选择,从而导致鉴定出一类新型的p38alpha抑制剂,该抑制剂含有以前未报道的双环杂环核。推进该系列的SAR,最终发现了5-(2,6-二氯苯基)-2-(2,4-二氟苯硫基)-6H-嘧啶[1,6-b]哒嗪-6-烯(VX -745)。VX-745具有出色的酶活性和选择性,并具有良好的药代动力学特性,并且在炎症模型中具有良好的体内活性。